CD20, technical only
Use
CD20 is a transmembrane phosphoprotein expressed on B lineage cells. Expression is first noted on the pre-B-cell stage and continues throughout all stages of B-cell maturation until reaching pro-B cell and plasma cell stage. CD20 antigen is observed on some precursor B lymphoid neoplasms, mature B-cell neoplasms, nodular lymphocyte predominant Hodgkin lymphoma, and in a subset of classical Hodgkin lymphomas.
Special Instructions
Not provided.
Limitations
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Methodology
Immunoassay (IHC)
Biomarkers
CD20
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fixed (Non-FFPE))
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours preferred).
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |